Allergan has acquired development and commercialization rights to interstitial cystitis/ bladder pain syndrome therapy LiRIS (lidocaine) from Taris Biomedical.
Allergan is paying $67.5m in cash upfront for the product which is currently in Phase II trials. The Irvine, California-based...